Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
6(50%)
Results Posted
50%(3 trials)

Phase Distribution

Ph phase_1
2
17%
Ph phase_2
4
33%
Ph phase_3
6
50%

Phase Distribution

2

Early Stage

4

Mid Stage

6

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
2(16.7%)
Phase 2Efficacy & side effects
4(33.3%)
Phase 3Large-scale testing
6(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

6

trials recruiting

Total Trials

12

all time

Status Distribution
Active(6)
Completed(6)

Detailed Status

Completed6
Active, not recruiting6

Development Timeline

Analytics

Development Status

Total Trials
12
Active
6
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (16.7%)
Phase 24 (33.3%)
Phase 36 (50.0%)

Trials by Status

completed650%
active_not_recruiting650%

Recent Activity

6 active trials
Showing 5 of 12
completedphase_2

A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis

NCT05357755
completedphase_2

A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06049017
active_not_recruitingphase_3

A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

NCT06295692
active_not_recruitingphase_3

A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis

NCT06095115
active_not_recruitingphase_3

A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

NCT06934226
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT05357755Phase 2

A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis

Completed
NCT06049017Phase 2

A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis

Completed
NCT06295692Phase 3

A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Active Not Recruiting
NCT06095115Phase 3

A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis

Active Not Recruiting
NCT06934226Phase 3

A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

Active Not Recruiting
NCT06095102Phase 3

A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)

Active Not Recruiting
NCT06220604Phase 3

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

Active Not Recruiting
NCT06143878Phase 3

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Active Not Recruiting
NCT05223868Phase 2

A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis

Completed
NCT05364554Phase 2

A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis

Completed
NCT05062200Phase 1

A Study of JNJ-77242113 in Healthy Japanese and Chinese Participants

Completed
NCT05703841Phase 1

A Study of JNJ-77242113 Following Oral Administration in Healthy Chinese Adult Participants

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12